KPV

KPV

10mg / Single Vial
$59.00
$59.00
Skip to product information
KPV
  • KPV
KPV

KPV

$59.00
$59.00
Size10mg
Quantity

Research Use Only

All products are intended solely for laboratory research and are not for human or animal consumption. By purchasing, the buyer agrees to use these products in compliance with all applicable laws.

KPV Overview

KPV is a small tripeptide derived from the C-terminus of α-MSH that retains signaling activity while lacking melanotropic effects. Through PepT1-mediated uptake in epithelial and macrophage models, KPV directly accesses intracellular compartments where it modulates NF-κB signaling and reduces expression of key cytokines including TNF-α, IL-1β, IL-6, and IL-8. Research models examine KPV's effects on cytokine signaling cascades, epithelial barrier dynamics through tight junction protein regulation, mucosal modeling in experimental systems, and antimicrobial properties in laboratory settings.

Dalmasso et al. (2008). Brzoska et al. (2008).

History

The cytokine-modulating properties of the KPV sequence were first identified in the late 1980s through structure-activity studies of α-MSH by Hiltz, Lipton, and colleagues. Systematic truncation experiments demonstrated that this C-terminal tripeptide retained significant immunomodulatory activity despite its minimal size, representing the smallest effective sequence for cytokine-modulating action. Subsequent mechanistic studies by Dalmasso et al. in 2008 elucidated the PepT1-mediated epithelial uptake mechanism, establishing KPV's potential for targeting signaling pathways in experimental mucosal models.

Hiltz & Lipton (1989). Dalmasso et al. (2008).

Research Findings

KPV has been extensively studied in cytokine signaling research, with investigations focusing on NF-κB pathway modulation, epithelial signaling models, barrier dynamics, and immune modulation in various experimental systems. Studies examine both its unique transporter-mediated delivery and potent cytokine-modulating mechanisms.

Key Areas of Research:

  • Cytokine: NF-κB, MAPK, suppression

  • Epithelial: Mucosal signaling, modeling

  • Barrier: Tight junction, permeability, integrity

  • Immune: Peptide-receptor, macrophage, T-cell

Together, these investigations demonstrate KPV's multifaceted cytokine-modulating actions through PepT1-mediated uptake and direct intracellular signaling modulation. As a minimal bioactive sequence, KPV provides a research framework for examining peptide-based cytokine mechanisms, epithelial immune signaling, and barrier dynamics in diverse experimental models.

Dalmasso et al., Gastroenterology, 2008

Brzoska et al., Inammation Research, 2008

Getting et al., Journal of Pharmacology and Experimental Therapeutics, 2003

References


Dalmasso G. et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 134(1):166-178.

Brzoska T . et al. (2008). α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Inflammation Research, 57(1):14-22.

Getting S.J. et al. (2003). The melanocortin peptide HP228 displays protective effects in acute models of inflammation and organ damage. Journal of Pharmacology and Experimental Therapeutics, 306(2):631-637.

You may also like